All In Biotech

NDA 050555 · Novartis

Tobrex

Tobramycin · Ophthalmic · Aminoglycoside Antibacterial

Last checked: Nov 19, 2026Latest source record: May 14, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Nov 25, 1981

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

50 Phase 3, 6 recruiting

FAERS reports

12,764

10,320 serious, 1,284 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

INDICATIONS AND USAGE TOBREX ® (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX (tobramycin ophthalmic ointment) 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 25, 1981 Original approval · Type 3 - New Dosage Form
1 products under this application
  • TOBREX · TOBRAMYCIN 0.3% · OINTMENT, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tobramycin" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use795
  • pneumonia776
  • drug ineffective727
  • acute kidney injury702
  • dyspnoea696
  • infective pulmonary exacerbation of cystic fibrosis611
  • death488
  • cough464
  • condition aggravated457
  • hospitalisation456
  • infection453
  • pyrexia436

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200485
2005102
200683
2007129
2008110
2009103
2010117
2011220
2012211
2013194
2014294
2015469
2016538
2017594
20181,083
20191,574
20201,391
20211,036
2022972
2023825
20241,046
2025895
2026692

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tobrex (Tobramycin)

2024 spending

$1.3M

Beneficiaries

3,787

4,802 claims

Per beneficiary

$345

$74.45 per unit

View as table
YearSpending
2020$0
2021$0
2022$258,472
2023$1,159,711
2024$1,304,703

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 791 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.